Percutaneous Management of Grade Ii Upper Urinary Tract Transitional Cell Carcinoma:

Abstract

Percutaneous surgery has proved safe and effective in treating superficial grade II upper tract transitional cell carcinoma. Offering an endoscopic approach electively to healthy individuals with a normal contralateral kidney seems viable.

Minimally Invasive Management of Upper Tract Malignancies: Renal Cell and Transitional Cell Carcinoma

“…Roupret and colleagues [75] performed a retrospective review of patients who underwent percutaneous surgery for upper tract TCC and reported 5-year disease-specific and tumor-free survival rates of 79.5% and 68%, respectively, for lowgrade or superficial TCC localized in the kidney. Jabbour and colleagues [68] reported disease-free rates comparable to those of nephroureterectomy in patients who had grade II TCC treated percutaneously. After a mean follow-up of 51 months, these investigators described an overall tumorspecific survival rate of 84%; the rate was 100% for grade 1, 94% for grade 2, and 62% for grade 3 disease.…”

“…Percutaneous access allows larger tumors to be resected throughout the collecting system [68,69]. The percutaneous approach is best indicated for patients who have larger renal pelvic tumors, collecting system tumors (greater than 1.5 cm), or bulky proximal ureteral tumors.…”

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC

“…Its advantages include high safety, less trauma, fast recovery, high overall survival rate, and fewer complications, and it is a better method for Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC patients with normal contralateral renal function. 4,5 In addition, chemotherapy, targeted therapy, and immunotherapy are also used to treat patients with upper urinary tract UC. For example, Erdafitinib was the first approved targeted drug for patients with locally advanced or metastatic UC with FGFR2 or FGFR3 gene mutations.…”